Atrovent Indication:

For maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.

Atrovent Mechanism Of Action:

Atrovent bromide is an anticholinergic agent. It blocks muscarinic cholinergic receptors, without specificity for subtypes, resulting in a decrease in the formation of cyclic guanosine monophosphate (cGMP). Most likely due to actions of cGMP on intracellular calcium, this results in decreased contractility of smooth muscle.

Atrovent Drug Interactions:

Not Available

Atrovent Food Interactions:

Not Available

Atrovent Generic Name:


  • Ipatropium Bromide
  • Ipratropium Bromide
  • N-Isopropylatropine

Drug Type:

Small Molecule; Approved


Inhalation (local)-minimal; Nasal-rapid and minimal

Toxicity (Overdose):

LD50=1001mg/kg (orally in mice)

Protein Binding:

Minimally (0 to 9% in vitro) bound to plasma albumin and a1-acid glycoproteins



Half Life:

Approximately 2 hours

Dosage Forms of Atrovent:

Aerosol, metered Respiratory (inhalation)
Solution Nasal
Liquid Nasal
Aerosol, metered Nasal
Spray, metered Nasal
Solution Respiratory (inhalation)
Liquid Respiratory (inhalation)

Chemical IUPAC Name:

[(1R,5R)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate

Organisms Affected:

Humans and other mammals

Atrovent to general, pharmacology

General, pharmacology..